EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access

Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis

Waqas Ullah iD, Harigopal Sandhyavenu iD, Amro Taha iD, Smitha Narayana Gowda, Maryam Mukhtar iD, Aravind Reddy Polam iD, Salman Zahid iD, David L Fischman iD, Michael P Savage iD, Sunil V Rao iD, Mohamad Alkhouli iD

Journal of the American Heart Association · 15.10.2024 · 13 (20)

DOI: 10.1161/jaha.122.032490 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, erschienen am 15.10.2024. Verfasst von Waqas Ullah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Thomas Jefferson University Hospitals Philadelphia PA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Optimal duration and choice of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention remain controversial. Methods and Results Digital databases (PubMed, Cochrane, and Embase) were queried to select all randomized controlled trials on a post–percutaneous coronary intervention population with acute coronary syndrome. Dual‐antiplatelet therapy (DAPT) with aspirin and clopidogrel for 12 months was compared with 4 major strategies: high‐potency, high‐ to low‐potency, low‐dose, and short‐duration DAPT. A network meta‐analysis was performed to compare the safety and efficacy of different antiplatelet strategies. This study was the second updated manuscript under the International Prospective Register of Systematic Review registration (CRD42021286552). Thirty‐two randomized controlled trials comprising 103 459 (51 750 experimental, 51 709 control) patients were included. Compared with DAPT with aspirin and clopidogrel for 12 months, high‐ to low‐potency DAPT (risk ratio [RR], 0.69 [95% CI, 0.52–0.92]) and aspirin+prasugrel containing DAPT for 12 months (RR, 0.84 [95% CI, 0.72–0.98]) had a significantly lower, whereas DAPT for 1 month followed by clopidogrel only (RR, 1.59 [95% CI, 1.06–2.39]) had a higher, incidence of major adverse cardiovascular events at 1 year (median follow‐up). Prasugrel (RR, 1.35 [95% CI, 1.09–1.66]) and ticagrelor (RR, 1.38 [95% CI, 1.17–1.62]) containing DAPT for 12 months had significantly higher rates, whereas high‐ to low‐potency DAPT (RR, 0.85 [95% CI, 0.63–1.15]) had no significant risk of major bleeding.

Conclusions

Aspirin and ticagrelor for 3 months, followed by aspirin and clopidogrel for the remaining duration, can be considered the optimal strategy for treating post–percutaneous coronary intervention patients with acute coronary syndrome because of a significantly reduced risk of major adverse cardiovascular events without increasing the risk of bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsHumansAspirinClopidogrelDrug Therapy, CombinationDual Anti-Platelet TherapyHemorrhageTreatment Outcome

Stichwörter der Autor:innen

acute coronary syndromedual‐antiplatelet therapypercutaneous intervention

Substanzen

AspirinClopidogrelPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Thomas Jefferson University Hospitals Philadelphia PA.
  • UT Health San Antonio San Antonio TX.
  • Weiss Memorial Hospital Chicago IL.
  • Houston Methodist DeBakey Heart and Vascular Center Houston TX.
  • University Hospitals of Leicester National Health Service Trust Leicester UK.
  • Oregon Health and Science University Portland OR.

ORCID-Profile: Waqas Ullah, Harigopal Sandhyavenu, Amro Taha, Maryam Mukhtar, Aravind Reddy Polam, Salman Zahid, David L Fischman, Michael P Savage, Sunil V Rao, Mohamad Alkhouli

Zitieren

APA

Ullah, W., Sandhyavenu, H., Taha, A., Narayana Gowda, S., Mukhtar, M., Reddy Polam, A., Zahid, S., Fischman, D. L., Savage, M. P., Rao, S. V., & Alkhouli, M. (2024). Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis. Journal of the American Heart Association, 13(20). https://doi.org/10.1161/jaha.122.032490

Vancouver

Ullah W, Sandhyavenu H, Taha A, Narayana Gowda S, Mukhtar M, Reddy Polam A, et al. Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis. Journal of the American Heart Association. 2024;13(20). doi:10.1161/jaha.122.032490

BibTeX
@article{Ullah2024,
  author = {Ullah, Waqas and Sandhyavenu, Harigopal and Taha, Amro and Narayana Gowda, Smitha and Mukhtar, Maryam and Reddy Polam, Aravind and Zahid, Salman and Fischman, David L and Savage, Michael P and Rao, Sunil V and Alkhouli, Mohamad},
  title = {Antiplatelet Strategy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Network Meta‐Analysis},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {20},
  doi = {10.1161/jaha.122.032490}
}
Kostenlos starten →